Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| DCC Convex Ltd. | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This is a clinical study aimed at evaluating the efficacy and safety of Eschscholzia tablets in adults with insomnia disorder symptoms. The study will be conducted at one center, participants will randomly be assigned to either the treatment or placebo. Neither the participants, nor the researchers will know who is receiving the treatment (double-blind). The study is also placebo-controlled, meaning some participants receive a dummy pill instead of the actual treatment, and it involves a parallel-group design, where the treatment and placebo groups are studied at the same time. The study is exploratory, meaning it is investigating new possibilities and is not yet fully conclusive.
The purpose of this study is to determine main efficacy and safety of the newly developed herbal medicinal product Eschscholzia tablets. A total of 100 subjects will be enrolled in the study and assigned to either Eschscholzia tablets or placebo.
The Local Ethics Committee at the clinical site has given their approval for the study to be run.
Male or female participats aged between 18 and 75 years (inclusive), generally healthy and with a self reported history of disturbed sleep on at least 3 nights per week for at least the prior 1 month with a self-reported impact on daytime functioning are allowed to take part in the study.
Overall, the study has the following visits in the clinic, planned for each patient: Screening visit, Study centre Visit 2, Final study centre Visit 3. Between these visits participants will go through a "run-in" period (1 week between Visit 1 and 2) and treatment period (1 month between visit 1 and 3), both at home. Upon visit 2 participants will obtain the study product. They will be asked to administer a daily dose of 2 tablets (either Eschscholzia tablets or Placebo) over a 4-week period, starting from Visit 2 and continuing until Visit 3. Every intake of study product should be noted on the sleep diary pages that the participants obtain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Verum Group: Eschscholzia tablets | Experimental | One Escholzia tablet (1.0 g) contains as active pharmaceutical ingredient: 0.503 g Eschscholzia californica Herba rec. tinct. conc. as the active pharmaceutical ingredient (API) corresponding 600 mg powdered herbal material. |
|
| Control Group: Placebo tablets | Placebo Comparator | A placebo tablet will be provided that matches the verum in its optical and sensorial properties and posology. Contains: microcrystalline cellulose, Colloidal anhydrous silica, glycerol distearate, caramel couleur and colorants. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Eschscholzia tablets | Drug | The intervention will be provided as swallowable "Eschscholzia tablets" (1.0 g) containing 0.503g Eschscholzia californica Herba rec. tinct. conc. as the active pharmaceutical ingredient (API) corresponding 600 mg powdered herbal material. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline over the 4-week treatment phase in perceived sleep quality, as measured by the summed area under the curve (summed up ISI AUC) of the Insomnia Severity Index (ISI) Total Score. | Min: 0 score points, Max: 28 score points Lower scores mean better outcomes The global effect of the investigational medicinal product (IMP) on sleep will be evaluated using the area under the curve (AUC) of repeatedly measured subjective insomnia severity, assessed by the ISI Total Score. | Change between baseline and over 4-week treatment phase |
| Change in perceived sleep quality over time during the treatment period, as assessed by the longitudinal profile of the change from baseline in ISI total score values at each post-baseline assessment time point | Endpoint evaluates changes in perceived sleep quality over time during treatment based on Insomnia Severity Index (ISI) change from baseline at each scheduled post-baseline assessment time point. | From baseline over the phase of the 4 weeks treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Time to reach a clinically relevant insomnia symptom severity reduction of -9 units on the ISI total score scale | Endpoint evaluates the time to response (TTR), defined as the first study day on which a subject achieves a clinically relevant reduction in insomnia severity, corresponding to a change from baseline of Δ ISI ≤ -9 points. | From baseline over the phase of the 4 weeks treatment |
Not provided
Inclusion Criteria:
Voluntary, written, informed consent to participate in the study
Self reported difficulty or maintaining sleep or waking too early, or daytime impairement or distress based on subject's information related to sleep pattern during at least the preceding month before screening.
Self reported history of disturbed sleep on at least 3 nights per week for at least the last 1 month before screening.
ISI total score ≥ 10
Confirmation of presence of insomnia diagnosis according to the ICD-10 F51.0/ICD-11 7A00 criteria by the physician upon anamnesis.
Reported Impact on daytime functioning associated with sleep maintenance as measured with question 7 of the ISI, Score >= 2
Freezing capacities available for storage of saliva samples.
Willingness and infrastructure available to run aktigraphic device (bed sensor) properly
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Diagnostics and Consultation Center Convex | Sofia | 1680 | Bulgaria |
IPD may be sharaable upon reasonable request
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo Tablets | Drug | A placebo tablet will be provided that matches the verum in its optical and sensorial properties and posology. Contains: microcrystalline cellulose, Colloidal anhydrous silica, glycerol distearate, caramel couleur and colorants. |
|
| Change in perceived sleep quality over time during the treatment and post-treatment period, as assessed by ISI AUC values at each intervention time point. | The secondary efficacy parameter ISI AUC over time is defined as the baseline-adjusted ISI AUC values calculated between consecutive assessment time points. ISI AUC values are available for the post-baseline intervention and follow-up visits on Days 9, 11, 15, 22, 29, and 36. Baseline adjustment is performed. A decrease (negative value) in ISI AUC is associated with a positive treatment effect, whereas an increase (positive value) indicates a negative treatment effect | From baseline over the phase of the 4 weeks treatment |
| Change in perceived overall sleep quality over time during the treatment, as assessed by the sleep diary composite score TSQ1 | The Total Sleep Quality Index 1 (TSQ1) is a composite parameter derived from daily sleep diary entries and is intended to quantify overall perceived sleep quality over time. TSQ1 is calculated at each diary time point as the arithmetic mean of four sleep quality subscores: Sleep Enjoyment, Well Rested, Physical Tension, and Psychological Tension. Each subscore is normalized to a common scale ranging from 0 to 100, with higher values indicating better sleep quality. For subscores reflecting negative aspects of sleep (physical and psychological tension), reverse coding is applied prior to normalization to ensure consistent score directionality. The resulting TSQ1 score ranges from 0 to 100, where higher values indicate better perceived sleep quality | From baseline over the phase of the 4 weeks treatment |
| Change in perceived overall sleep quality over time during the treatment, as assessed by the sleep diary subscores | Patients will complete the daily diary from study day 2 throughout the whole study duration until the morning of study day 36. Sleep quality is assessed with four NRS (scale from 0 (very low) to 10 (very high)) with the parameters: physical tension (QPHY_D), psychological tension (QPSY_D), sleep enjoyment (QEnj_D) and restedness (QRest_D) and sleep quality (SQ_D). Further, the number of awakenings (NWAK_D), duration of awakenings (DWAK_D), sleep onset latency (SOL_D) is assessed. | From baseline over the phase of the 4 weeks treatment |
| ISI Responder criteria assessed at the end of intervention on visit 3 | ISI Responder criteria assessed at the end of intervention on visit 3 (day 36):
| From baseline to the end of treatment after 4 weeks treatment |
| Change between baseline and over 4-week treatment phase in daytime sleepiness symptoms severity as measured with the Epworth Sleepiness Scale (ESS) | Min: 0 score points, Max: 24 score points Lower scores mean better outcomes | From baseline to the end of the treatment after 4 weeks |
| Change between baseline and over 4-week treatment phase in Profile of Mood states as measured with the POMS-2 questionnaire (POMS-2). | The POMS-2 includes the following primary scales: Tension-Anxiety Depression-Dejection Anger-Hostility Fatigue-Inertia Confusion-Bewilderment Vigor-Activity (positive scale) Higher raw scores on negative scales indicate greater mood disturbance. Higher raw scores on the Vigor-Activity scale indicate positive mood states. | Change between baseline and over 4-week treatment phase |
| Change between baseline and over 4-week treatment phase in state anxiety as measured with the State-Trait-Anxiety-Inventory (STAI-Y1 & Y2). | STAI-Y1: Measures state anxiety (temporary and situational anxiety). STAI-Y2: Measures trait anxiety (general and long-standing anxiety tendencies). Both STAI-Y1 & STAI-Y2 are individually assessed as follows Minimum Score: 20 (low anxiety) Maximum Score: 80 (high anxiety) Lower scores mean better outcomes | Change between baseline and over 4-week treatment phase |
| Change between baseline and over 4-week treatment phase in anxiety disorders as per the assessment of the clinician on the HAM-A scale (HAM-A). | Minimum Score: 0 (no anxiety) Maximum Score: 56 (severe anxiety) Lower scores mean better outcomes | Change between baseline and over 4-week treatment phase |
| Change between baseline and over 4-week treatment phase in psychological well-being as measured with the Depression, Anxiety, and Stress Scale (DASS-21). | has 21 items, diivided into three subscales: Depression (7 items) Anxiety (7 items) Stress (7 items) Minimum Score per Subscale: 0 Maximum Score per Subscale (adjusted): 42 lower scores mean better outcomes | Change between baseline and over 4-week treatment phase |
| Subjective efficacy | Patient's perceived efficacy will be assessed upon final visit 3 by asking the question how the subjects would rate the effectiveness of the study product to treat insomnia, sleeping problems and/or accompanying symptoms on a scale: "bad" = 0, "average" = 1, "good" = 2, "very good" = 3. | Day 36 |
| Acceptance of the treatment | Patient's perceived acceptance is assessed upon final visit V3 by asking "would you take the test medication again to treat insomnia, sleeping problems and/or accompanying symptoms? Answers possible: "yes" or "no". | On day 36 |
| Subjective tolerability | Patient's perceived tolerability will be assessed upon final visit 3 by asking the question how they rate their self-perceived tolerability of the IP on a scale: "bad" = 0, "average" = 1, "good" = 2, "very good" = 3. | On Day 36 |
| Change between baseline and over 4-week treatment phase in physiological sleep quantity and quality and physiological measures via actigraphy (wearable). | In this study, actigraphy sleep data will be delivered using the multi-sensory Fitbit tracker "Fitbit Charge 6" Actigraphic parameters, which are recorded on a daily basis, will be handled and analysed in general consistency with the sleep diary data • Data log data are averaged daily for all parameters applicable Parameters:
| Change between baseline and over 4-week treatment phase |
| Rate/kind of adverse events | on day 36 |
| Blood pressure | Blood pressure (BP): Systolic and diastolic BP will be assessed by using an automated BP measurement device. | Change between baseline and day 36 |
| Blood pulse | Blood pulse will be assessed by using an automated measurement device | Change between baseline and day 36 |
| Change in Blood safety parameters | The following factors will be analysed as per standard normal ranges for adults (f/m) by an external independent and certified medical diagnostic laboratory:
| Change between baseline and day 36 |
| Rate/kind of comedication | Change between baseline and day 36 |
| Treatment compliance | Upon Visit 3, product intake compliance will be verified by counting the remaining tablets of the study product returned by subjects. Limits for subjects to be compliant is an intake of study product within 80% - 120% of the intended study product intake schedule. | on day 36 |
| Change in biomarker for stress between baseline and over 4-week treatment phase via the salivary evening cortisol levels (8 p.m.) | Assessed at 8 p.m. ±20 minutes and delivered by the analytical laboratory Parameters: • Evening cortisol level | Change from baseline days 6/7 to chronic treatment after days 34/35 |
| Change in biomarker for sleep readiness between baseline and over 4-week treatment phase via the salivary evening melatonin level (8 p.m.) | Assessed at 8 p.m. ±20 minutes and delivered by the analytical laboratory Parameters: • Evening melatonin level | Change from baseline days 6/7 to chronic treatment by days 34/35 |
| Change between baseline and over 4-week treatment phase in ratio of biomarker evening melatonin level/ evening cortisol level (8 p.m.) | Assessed at 8 p.m. ±20 minutes and delivered by the analytical laboratory. Ratio = Evening melatonin level/Evening Cortisol level | Change from baseline days 6/7 to chronic treatment by days 34/35 |
| Change between baseline and over 4-week treatment phase in biomarker for chronic stress via the CAR determined | Assessed at 8 p.m. ±20 minutes and delivered by the analytical laboratory. The saliva samples in the morning are collected three times in the first hour after waking (at awakening as well as 30 and 45 min after awakening) to assess the CAR as a physiological reaction to awakening. The area under the curve (1) with respect to ground (AUCG), and (2) with respect to increase (AUCI) is calculated using the following formulae (Pruessner and colleagues, 2003): | Change from baseline days 6/7 to chronic treatment by days 34/35 |